Patents Examined by Bridget E. Bunner
  • Patent number: 10653752
    Abstract: Methods and compositions for the use of long-acting hematopoietic factor protein analogs for accelerating hematopoietic recovery in subjects who have been or will be exposed to radiation are disclosed.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: May 19, 2020
    Assignee: Bolder Bio Technology, Inc.
    Inventors: George N. Cox, Christie M. Orschell
  • Patent number: 10654924
    Abstract: Binding molecules to IL-17A. The binding molecules are useful in the treatment of disorders, for example psoriasis.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: May 19, 2020
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Bryan Edwards, Ulla Lashmar, Brian McGuinness, Mike Romanos, Thomas Sandal, Yumin Teng
  • Patent number: 10640560
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: May 5, 2020
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Jeffrey T. L. Smith, John A. Latham, Mark Litton, Randall Schatzman
  • Patent number: 10633439
    Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: April 28, 2020
    Assignees: MORPHOSYS AG, GALAPAGOS NV
    Inventors: Jan Dominik Haas, Jürgen Klattig, Nick Ernest Rene Vandeghinste
  • Patent number: 10626372
    Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, and NK cells.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: April 21, 2020
    Assignee: FATE THERAPEUTICS, INC.
    Inventors: Bahram Valamehr, Raedun Clarke
  • Patent number: 10618966
    Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise the amino acid sequence, nucleic acids that encode the amino acid sequences, compounds or constructs, pharmaceutical compositions comprising the amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: April 14, 2020
    Assignee: Ablynx N.V.
    Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert
  • Patent number: 10611832
    Abstract: Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1? binding molecules (e.g., IL-1? binding antibodies and fragments thereof). The present disclosure also relates to methods for prevention or treatment of cardiovascular events and/or cardiovascular diseases, including by reducing a cardiovascular event or disease.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: April 7, 2020
    Assignee: XOMA (US) LLC
    Inventors: Patrick J. Scannon, Alan M. Solinger, Jeffrey D. Feldstein
  • Patent number: 10611823
    Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: April 7, 2020
    Assignee: HANSSEN BIOTECH, INC
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 10604756
    Abstract: The present invention relates to methods for protecting against damage caused by radiation and/or chemotherapy, and methods for treating bone marrow damage by reducing/inhibiting Latexin expression and/or Latexin activity. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising an antagonist that reduces expression and/or activity of latexin, wherein latexin is a latexin polynucleotide variant and/or a latexin polypeptide variant that binds to the antagonist.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 31, 2020
    Assignee: University of Kentucky Research Foundation
    Inventors: Gary Van Zant, Ying Liang, Yi Liu
  • Patent number: 10604566
    Abstract: The present invention provides antagonists of IL-17C for use in the treatment and/or prevention of atopic dermatitis and related conditions.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 31, 2020
    Assignees: Galapagos NV, MorphoSys AG
    Inventors: Nick Ernest René Vandeghinste, Reginald Christophe Xavier Brys
  • Patent number: 10596228
    Abstract: A novel IFN-?/? independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-?1, IFN-?2, IFN-?3, based inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-? proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-?R1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-?R1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: March 24, 2020
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Sergei V. Kotenko, Grant F. Gallagher
  • Patent number: 10597438
    Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: March 24, 2020
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 10590182
    Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: March 17, 2020
    Assignee: The Regents of the University of California
    Inventors: Wendell A. Lim, Leonardo Morsut, Kole T. Roybal, Justin Thomas Farlow, Satoshi Toda
  • Patent number: 10583181
    Abstract: The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF/TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.
    Type: Grant
    Filed: February 11, 2018
    Date of Patent: March 10, 2020
    Inventor: Atsuo Ochi
  • Patent number: 10583191
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: March 10, 2020
    Assignees: MOSAIC BIOMEDICALS SLU, FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA DE VALL HEBRON, FUNDACIÓ PRIVADA INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira
  • Patent number: 10583182
    Abstract: The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF/TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.
    Type: Grant
    Filed: February 11, 2018
    Date of Patent: March 10, 2020
    Inventor: Atsuo Ochi
  • Patent number: 10576131
    Abstract: Disclosed is a vaccine, preferably for use in the prevention or treatment of an interleukin 23 (IL-23) related disease, that includes a peptide bound to a pharmaceutically acceptable carrier, wherein the peptide is QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322), GHHWETQQIPSLSPSQPWQRL QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9269-C1), or QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9269-C2), especially QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322) and wherein the IL-23 related disease is one or more of psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, preferably type 1 diabetes, atherosclerosis, inflammatory bowel disease (IBD)/M.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: March 3, 2020
    Assignee: AFFIRIS AG
    Inventors: Guenther Staffler, Dorian Winter
  • Patent number: 10577424
    Abstract: An isolated monoclonal antibody or the antigen binding portion thereof that specifically binds human VISTA. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody or the antigen binding portion thereof are also provided. The present disclosure further provides a bispecific molecule, and a pharmaceutical composition comprising the antibody or the binding moieties thereof, as well as a treatment method using an anti-VISTA antibody or the antigen binding portion thereof of the present disclosure.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: March 3, 2020
    Assignee: Beijing Mabworks Biotech Co., Ltd.
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • Patent number: 10577414
    Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to the patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 3, 2020
    Assignee: Cephalon, Inc.
    Inventors: Christopher O'Brien, James Zangrilli, Tushar Shah, Guy Brusselle
  • Patent number: 10570206
    Abstract: The present invention relates in general to the field of TNF ligand family members. In more detail the present invention relates to polypeptides comprising at least three components A, each of which comprises the sequence of a TNF homology domain (THD) of a TNF ligand family member, or a functional derivative thereof, and comprising at least one component B consisting of a VL region and a VH region linked directly to each other with a linker sequence L which has a length of <12 amino acids. Furthermore, the present invention also relates to nucleic acids encoding such polypeptides and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: February 25, 2020
    Assignee: UNIVERSITAT STUTTGART
    Inventors: Klaus Pfizenmaier, Roland Kontermann, Martin Siegemund